Morgan Bayer is an assistant editor for Targeted Oncology and Targeted Therapies in Oncology.
The FDA approved adagrasib with cetuximab for KRAS G12C-mutated CRC and an AI-driven mortality models improve palliative care. We also cover data on datopotamab deruxtecan showing promise in HER2-low breast cancer, zanubrutinib plus venetoclax achieving 100% ORR in high-risk CLL/SLL, and an overview of treatments HER2-targeted treatments highlighting T-DXd in CNS involvement.
Douglas B. Johnson, MD, MSCI, offers a comprehensive exploration of the nuances for using neoadjuvant therapy, addressing various treatment combinations, along with recommendations for first-line systemic therapy.
Recent approvals herald novel strategies for addressing advanced or metastatic breast cancer with ESR1 mutations.
Endometrial cancer scores 2 approvals, and PFS benefit is observed with amivantamab/chemotherapy in NSCLC. We also cover T-DXd efficacy in HER2 breast cancer with brain metastasis and the approval of repotrectinib for NTRK-positive solid tumors.
Recommendations on adoptive cell therapy with tumor-infiltrating lymphocytes that address the newly approved therapy lifileucel explore safe administration practices and optimal patient selection based on individual characteristics.
In a prognostic study, an artificial intelligence model significantly outperformed oncologists in predicting short-term mortality, resulting in a 60% positive predictive value vs 34.8%, which involved 57 physicians and 17 advanced practice clinicians.
Delving into the power of ADCs and intriguing data presented at the 2024 ASCO Annual Meeting, including benefits observed with nivolumab-cabozantinib in advanced RCC and the durable responses seen in endometrial cancer with envafolimab-lenvatinib. We also cover data on JNJ-6420 for metastatic CRPC, and the improvements seen with enfortumab vedotin plus pembrolizumab in urothelial cancer.
Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.
In clinical trials, dostarlimab continues to show a 100% CR in dMMR rectal cancer, camrelizumab plus rivoceranib improved survival in untreated uHCC, lorlatinib provided durable PFS in ALK+ lung cancer. We also cover the acknowledged BLA for zolbetuximab and the meaningful PFS achieved with ibrutinib/venetoclax in CLL/SLL.
The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.
Neoadjuvant enfortumab vedotin displayed promising outcomes for cisplatin-ineligible MIBC patients, achieving a 2-year EFS rate of 62.0%. Safety was affirmed with no treatment-related delays in surgery.
The inavolisib regimen, designed for PIK3CA-mutated breast cancer, and NVL-655 for ALK-positive NSCLC, have received FDA breakthrough designations, and infigratinib has lost FDA approval for cholangiocarcinoma. We also discuss targeted therapies reshaping NSCLC treatment, and the safety and efficacy of TNO155 combinations across various solid tumors.
Interim results show promising efficacy of palazestrant/ribociclib in ER+/HER2– metastatic breast cancer, an approval for tarlatamab-dlle, and data suggesting early ctDNA kinetics as a potential pharmacodynamic biomarker. We also cover the initiation of dosing quaratusugene ozeplasmid/atezolizumab in SCLC and more.
A correlation between non–small cell lung cancer and influenza shows a decrease in cancer survival rates.
Experts explore challenges in brain tumor management, and nivolumab/ipilimumab fails to improve PFS in NSCLC. We also cover access to 177Lutetium-PSMA-617, developments in mRNA cancer vaccine WGc-043, and antibody-drug conjugate 9MW2821 in esophageal cancer.
According to a recent analysis, preliminary circulating tumor DNA kinetics could serve as an early pharmacodynamic biomarker, offering potential for early biologic proof of concept.
A BLA for subcutaneous nivolumab in solid tumors, lenvatinib becoming primary treatment in thyroid cancer, and expert discussions on IO/TKI combos in RCC. We also cover positive results from acalabrutinib combination in MCL and pembrolizumab combination in HER2-positive gastric cancer.
T-DXd enhances survival in HR+/HER2-low breast cancer, and immunotherapy combo is recommended for advanced SCLC. We also highlight recent FDA approvals and challenges associated with legislative changes.
EG-70, a novel, nonviral gene therapy, elicited a 73% complete response at any time for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Updated guidelines for small cell lung cancer were developed with an expert panel assembled by the American Society of Clinical Oncology and Ontario Health.
Recent FDA approvals such as tovorafenib, nogapendekin, and alectinib, are included in this recap. We also cover boxed warnings for CAR T-cell therapies and analysis advancements for papillary thyroid microcarcinoma.
In the frontline, patient body mass index plays a prognostic role when using atezolizumab plus bevacizumab vs lenvatinib for patients with advanced hepatocellular carcinoma.
In this weekly recap ODAC endorses MRD for accelerated myeloma trial approval, research delves into ovarian cancer trends in Asian American populations, amivantamab’s variable efficacy in NSCLC, and more.
The FDA approves T-DXd for HER2+ tumors; SynKIR-310 trials begin, and experts debate FLOT vs. CROSS in GEJ cancer in this week’s recap article.
Emerging NK-cell therapies offer faster, safer alternatives to CAR T-cell therapy, improving accessibility and reducing manufacturing challenges. T-DXd shows promise in treating HER2+ tumors, and HPV vaccine offerings during abortion care visits improve vaccination rates.
Recommendations for non–small cell lung cancer biomarker testing in early-stage disease were discussed in a presentation regarding metastatic lung cancer by Christine M. Lovly, MD, PhD.
This week's Targeted Pulse focuses on the latest in cervical cancer, the FDA ODAC's vote for cilta-cel, and more.
This week's Targeted Pulse focuses on the latest in the treatment landscapes of small cell lung cancer, myeloma, and more.
From bispecific antibodies transforming B-cell lymphoma treatment to immunotherapy breakthroughs in breast cancer and gene therapy innovations for hematologic malignancies, recent advancements offer hope.